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Introduction {#sec1}
============

Duchenne muscular dystrophy (DMD) is one of the most common types of muscular dystrophy with onset in childhood. DMD patients show severe and progressive muscle atrophy and weakness, eventually resulting in a loss of walking ability and respiratory deficiency ([@bib14]). The causative gene, *DMD*, encodes the DYSTROPHIN protein, which binds F-actin and sarcolemma in the cytoskeleton ([@bib19]). The majority of DMD patients show deletions or mutations in *DMD*, resulting in a loss of DYSTROPHIN protein expression ([@bib50]). Since the restoration of DYSTROPHIN expression has been thought to be a definitive treatment for DMD, several therapeutic approaches have been investigated, such as mutation-specific drug exon skipping ([@bib21], [@bib30]), gene therapy ([@bib14], [@bib35]), and cell therapy ([@bib49]).

Among these approaches, cell therapy is expected to be the most promising because adult muscle stem cells (MuSCs), or satellite cells, possess robust regeneration potential for injured muscle. Previous studies have shown that transplanted adult MuSCs into model mice of muscular dystrophy fuse to the host muscle fibers and recover muscular function, suggesting regenerative properties ([@bib7], [@bib25], [@bib28], [@bib40], [@bib47], [@bib51]). However, the expansion of adult MuSCs with stemness is difficult ([@bib15], [@bib28], [@bib32], [@bib40]). On the other hand, fetal MuSCs can be expanded without compromising stemness and have higher engraftment efficiency than adult MuSCs ([@bib48]).

Human induced pluripotent stem cells (hiPSCs) are an attractive cell source for various cell therapies due to their proliferation and differentiation potential ([@bib46]). In the field of muscular dystrophy, several types of skeletal muscle progenitors with regeneration potential for injured muscle have been differentiated from hiPSCs via the virus-mediated overexpression of myogenic transcription factors ([@bib1], [@bib13], [@bib37], [@bib38], [@bib45]). [@bib13] reported that their muscle progenitors, iPAX7, exerted particularly high regenerative potential when grafted into DMD model mice. However, the safety of these cells, especially tumorigenicity, must be carefully evaluated before clinical trials since the hiPSCs were modified with a doxycycline-inducible lentiviral vector encoding PAX7. Transgene-free protocols that recapitulate the development of muscle lineage beginning with iPSCs by the step-wise addition of small chemicals and growth factors have also been reported ([@bib4], [@bib6], [@bib8], [@bib9], [@bib44], [@bib52]). Although these protocols have lower health risks compared with iPAX7, the muscular regeneration is weaker ([@bib20]).

Here, we report a novel transgene-free differentiation protocol from hiPSCs into fetal MuSCs with higher regeneration potential than iPAX7. Using a GFP reporter line with the dermomyotome marker PAX3 knocked in, we found that relatively long and strong activation of the WNT/β-CATENIN signaling pathway leads to the efficient induction of PAX3-GFP-positive dermomyotome-like cells. To visualize the myogenic lineage commitment, we generated a tdTomato reporter line with the myogenic progenitor marker MYF5 knocked in and examined the differentiation condition of muscle lineage cells from dermomyotome-like cells. Interestingly, the characteristics of MYF5-tdTomato-positive cells significantly changed with the duration of the differentiation steps. MYF5-tdTomato-positive cells at the early stage of differentiation resembled early myogenic progenitors, whereas those at the later stage resembled fetal MuSCs and expressed *PAX7*. The late-stage MYF5-tdTomato-positive cells recovered DYSTROPHIN and were maintained as PAX7-expressing satellite-like cells when grafted into DMD-null/NSG mice. Moreover, the limbs in which the cells were engrafted showed significantly higher contraction compared with control limbs. Thus, hiPSC-derived late-stage MYF5-positive cells, such as MuSCs, show good regenerative properties and should be investigated for transplantation therapy in the future.

Results {#sec2}
=======

Optimized Induction Method of Dermomyotome-like Lineage from hiPSCs with PAX3-GFP Reporter Line {#sec2.1}
-----------------------------------------------------------------------------------------------

To screen for the optimal condition that induces dermomyotome-like lineage from hiPSCs, we established the PAX3-GFP knockin 201B7 hiPSC line ([@bib46]) using the BAC construct-based recombination method ([Figure S1](#mmc1){ref-type="supplementary-material"}A). We confirmed the recombination by quantitative real-time PCR ([Figure S1](#mmc1){ref-type="supplementary-material"}B) and selected clone no. 142 as a heterozygous targeted clone. After conventional embryoid body formation, GFP-positive cells were observed and isolated by flow cytometry ([Figure S1](#mmc1){ref-type="supplementary-material"}C and S1D). *PAX3* expression in the GFP-positive population was confirmed by RT-PCR ([Figure S1](#mmc1){ref-type="supplementary-material"}E) and immunostaining ([Figure S1](#mmc1){ref-type="supplementary-material"}F). Then we optimized the dermomyotome induction condition by monitoring PAX3-GFP expression. Using the neural crest marker CD271, we excluded neural crest cells from the dermomyotome lineage ([Figures S2](#mmc1){ref-type="supplementary-material"}A--S2C), since PAX3 is also known as a marker of neural crest lineage ([@bib16]). Previously, the inhibition of transforming growth factor β signaling by SB431542 (SB) was reported to promote the myogenic differentiation of human pluripotent stem cells ([@bib24]), and the activation of WNT signaling by the inhibition of glycogen synthase kinase-3β(GSK-3β) was also reported to promote myogenic differentiation through dermomyotome formation ([@bib5], [@bib11], [@bib51]). Therefore, we attempted to induce dermomyotome lineage by combining SB and a GSK-3β inhibitor, CHIR99021 (CHIR) ([Figure 1](#fig1){ref-type="fig"}A). First, we optimized the concentration of CHIR in chemically defined medium (CDMi) supplemented with 10 μM SB ([Figure 1](#fig1){ref-type="fig"}B). Dermomyotome lineage was assessed as the PAX3-GFP-positive and CD271-negative population by fluorescence-activated cell sorting. PAX3+CD271− dermomyotome lineage was robustly induced when 10 μM CHIR was added for 14 days ([Figure 1](#fig1){ref-type="fig"}B). Accordingly, we optimized the SB concentration supplemented with 10 μM CHIR. The addition of 5 or 10 μM SB robustly promoted the PAX3+CD271− population in more than 90% of differentiated cells ([Figure 1](#fig1){ref-type="fig"}C). We confirmed step-wise differentiation by analyzing the expression of an early mesoderm marker, *T* ([@bib17]), a paraxial mesoderm marker, *TBX6* ([@bib10]), and a dermomyotome marker, *SIX1* ([@bib34]) ([Figure 1](#fig1){ref-type="fig"}D). The induction of *T* and *TBX6* was promoted by the addition of 10 μM CHIR and 0 or 5 μM SB ([Figure 1](#fig1){ref-type="fig"}D), suggesting that a high CHIR dose dominantly promotes early mesoderm and paraxial mesoderm differentiation. On the other hand, the induction of *SIX1* was specifically promoted by the addition of 10 μM CHIR and 5 μM SB ([Figure 1](#fig1){ref-type="fig"}D), suggesting that SB treatment is necessary to promote dermomyotome specification from paraxial mesoderm. We defined the addition of 10 μM CHIR and 5 μM SB in CDMi as the dermomyotome induction condition. Time course expression profiling of the marker genes was performed to confirm the step-wise differentiation toward dermomyotome ([Figure 1](#fig1){ref-type="fig"}E). The expression level of *T* first reached a peak at day 2, and the expression level of *TBX6* reached a peak at day 6 ([Figure 1](#fig1){ref-type="fig"}E). The expression level of two dermomyotome markers, *PAX3* and *MEOX1*, gradually increased during the 14 days of differentiation ([Figure 1](#fig1){ref-type="fig"}E). *NOGGIN*, *PARAXIS*, *DMRT2*, *ALX4*, and *EN1* were used as dermomyotome markers ([@bib31], [@bib42]), CDMi supplemented with 10 μM CHIR and 5 μM SB also gradually increased the expression of these dermomyotome markers during the 14-day differentiation ([Figure 1](#fig1){ref-type="fig"}F). These results suggest that the dermomyotome induction condition mimics the developmental steps toward dermomyotome. Morphologically, PAX3-GFP-positive cells represented an epithelial cell-like structure at day 14 ([Figure 1](#fig1){ref-type="fig"}G). Several recent studies, recapitulating the development of muscle lineage, differentiated hiPSCs by modulating signaling pathways to induce a paraxial mesoderm fate and then a dermomyotome fate ([@bib8], [@bib18], [@bib44]). Method S ([@bib44]) and method C ([@bib8]) were selected to be compared with our protocol, method Z ([Figure 2](#fig2){ref-type="fig"}A). Method Z significantly increased the PAX3+CD271− population at days 6 and 12 of differentiation ([Figure 2](#fig2){ref-type="fig"}B). These three methods did not show much difference in *T* expression at day 2; however, method Z significantly increased *TBX6*, *PAX3*, *PARAXIS*, and *DMRT2* expression at days 6 or 12 of the differentiation ([Figure 2](#fig2){ref-type="fig"}C). Previously, we demonstrated that the addition of basic fibroblast growth factor (bFGF), hepatocyte growth factor (HGF), and insulin growth factor 1 (IGF-1) to serum-free medium could promote myogenic differentiation from paraxial mesoderm in mouse embryonic stem cell differentiation culture ([@bib41]). To induce myogenic differentiation, after 12 days differentiation, cells from each method were passaged to Matrigel-coated 6-well plates (40,000 cells/well) and stimulated by SFO3 medium supplemented with 10 ng/mL bFGF, 10 ng/mL IGF, and 10 mg/mL HGF ([Figure S2](#mmc1){ref-type="supplementary-material"}D). Method Z produced more myogenic cells at day 38 of the differentiation ([Figures 2](#fig2){ref-type="fig"}D and 2E). The myogenic differentiation efficiency was well correlated with the induction of PAX3+CD271− in each method ([Figures 2](#fig2){ref-type="fig"}B and 2E). Furthermore, method Z remarkably increased both myogenic progenitor marker (*MYF5*) gene expression at day 19 and skeletal muscle marker (*MYH3*, *MYOD1*, *MYOG*) gene expression at day 38 ([Figure S2](#mmc1){ref-type="supplementary-material"}E). To conclude, using a PAX3-GFP reporter line, we optimized an induction method to differentiate a dermomyotome-like lineage from hiPSCs using CDMi supplemented with 10 μM CHIR and 5 μM SB with higher efficiency than previous reports.Figure 1Screening with PAX3-GFP reporter line to optimize dermomyotome lineage induction from hiPSCs(A) The step-wise differentiation protocol for hiPSC-derived dermomyotome. hiPSCs were plated in Matrigel-coated plates cultured in Stemfit (AK02N) for 3 days. The medium was changed to CDMi supplemented with SB431542 (SB) and CHIR99021 (CHIR) and then cultured for 14 days. Cells were passaged on day 7 and as single cells thereafter on a Matrigel-coated plate.(B) hiPSCs were treated with SB (10 μM) and CHIR (0, 1, 5, 10, or 20 μM). The histogram shows the ratio of PAX3+CD271− cells in the whole cell population. CHIR increased the PAX3+CD271− cell population dose dependently. 10 μM CHIR and 10 μM SB induced 90% PAX3+CD271− cells. CHIR (20 μM) was toxic to hiPSCs and caused cell death (data not shown). Data of three independent experiments are shown as means ± SD. N.A., not available.(C) hiPSCs were treated with CHIR (10 μM) and SB (0, 5, 10, 20, or 30 μM). The histogram shows the ratio of PAX3+CD271− cells in the whole cell population. 10 μM CHIR and 5 μM SB induced 95% PAX3+CD271− cells. Data of three independent experiments are shown as means ± SD.(D) mRNA expressions of *T* (day 6), *TBX6* (day 6), and *SIX1* (day 14) induced by CHIR and SB. Cells were treated with CHIR and SB at the indicated concentrations (μM). Data of three independent experiments are shown as means ± SD.(E) Time course of the mRNA expression of *BRACHYURY (T)*, *TBX6*, *PAX3*, and *MEOX1* in hiPSCs treated with 10 μM CHIR and 5 μM SB. The results are shown relative to values of human teratoma cells. Data of three independent experiments are shown as means ± SD. Primitive streak marker (*T*), paraxial mesoderm marker (*TBX6*), and dermomyotome marker (*SIX1*) were strongly upregulated on days 2, 6, and 14, respectively.(F) Time course of the mRNA expression of the dermomyotome markers *NOGGIN*, *PARAXIS*, *DMRT2*, *ALX4*, and *EN1* on days 0, 2, 6, and 14 of the differentiation. Dermomyotome marker genes time dependently increased in this step-wise protocol. Data of three independent experiments are shown as means ± SD. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.(G) Phase and fluorescence images of PAX3-GFP reporter cells differentiated using the step-wise protocol in (A). Almost all of the differentiated cells were GFP+ cells. Scale bars, 100 μm.Figure 2Comparison of the Dermomyotome Differentiation from hiPSCs with Published Methods(A) Timeline of the dermomyotome differentiation using method Z (Zhao et al. this work), method S ([@bib44]), and method C ([@bib8]).(B) Fluorescence-activated cell sorting (FACS) analysis of PAX3 and CD271 at day 6 (D6) and day 12 (D12) of the differentiation. The histogram shows the ratio of PAX3+CD271− cells in the whole cell population. Data of more than three independent experiments are shown as means ± SD. ^∗∗∗^p \< 0.001.(C) Time course of the mRNA expression of *BRACHYURY (T)*, *TBX6*, *PAX3*, *PARAXIS*, and *DMRT2* during the dermomyotome differentiation using method Z, method S, and method C. Data of more than three independent experiments are shown as means ± SD. ^∗^p \< 0.05, ^∗∗∗^p \< 0.001.(D) After 12 days of differentiation, cells were passaged on Matrigel-coated plates at the same cell density and stimulated with myogenic differentiation using SFO3 medium supplemented with 10 ng/mL bFGF, 10 ng/mL IGF, and 10 mg/mL HGF until day 38. Immunohistochemistry of myosin heavy chain (MHC), MYOD1, and DAPI. Scale bars, 50 μm.(E) Percentage of the MHC+ area to the whole culture area. Data of more than three independent experiments are shown as means ± SD. n = 6--8; ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.

Myogenic Induction from Dermomyotome-like Lineage {#sec2.2}
-------------------------------------------------

Next, we analyzed the property of the myocytes differentiated from the dermomyotome-like lineage cells ([Figure 3](#fig3){ref-type="fig"}A). PAX3-GFP-positive dermomyotome-like cells differentiated into infant myotubes expressing PAX3-GFP by around day 35 ([Figure S3](#mmc1){ref-type="supplementary-material"}A). After the emergence of infant myotubes, the culture medium was switched to conventional muscle maturation medium based on the low concentration of horse serum to mature the myotubes ([@bib33]) ([Figure 3](#fig3){ref-type="fig"}A). At around 8 weeks of differentiation, PAX3-GFP-negative mature myotubes were observed in the culture ([Figure S3](#mmc1){ref-type="supplementary-material"}B). These mature myotubes expressed myosin heavy chain and had MYOG-positive multi-nuclei ([Figure S3](#mmc1){ref-type="supplementary-material"}C). After 10 weeks of differentiation, spontaneous twitching was observed ([Video S1](#mmc2){ref-type="supplementary-material"}), which indicates mature myotube formation. According to these data, we successfully developed a step-wise myogenic differentiation protocol from hiPSCs to mature myotubes via dermomyotome-like lineage ([Figures 1](#fig1){ref-type="fig"}A and [3](#fig3){ref-type="fig"}A).Figure 3Myogenic Induction from Dermomyotome Lineage(A) Schematic representation of the myogenic induction and skeletal muscle maturation. Dermomyotome-like cells derived from hiPSCs were plated as single cells in Matrigel-coated plates cultured in CDMi supplemented with 10 μM Y-27632 for 3 days. The medium was changed to SFO3 (0.2% BSA, 0.1 mM 2-ME) supplemented with 10 ng/mL bFGF, 10 ng/mL HGF, and 10 ng/mL IGF-1. After 1 more week of culture, the medium was changed to SFO3 supplemented with 10 ng/mL HGF. After an additional week of culture, the medium was changed to SFO3 supplemented with 10 ng/mL HGF and 10 ng/mL IGF-1. On differentiation day 38, the medium was changed to DMEM supplemented with 2% HS, 5 μm SB 431542, and 10 ng/mL IGF-1 until day 84.(B) The time course of MYF5+ cells during the differentiation in C3, E16, and A24 cell lines as determined by FACS. Data of three independent experiments are shown as means ± SD.(C) Representative bright-field (Phase, Ph) and tdTomato images of live cultures of MYF5-tdTomato cells at 4 and 12 weeks in C3 cell line.(D and E) MYF5+ and MYF5− cells were sorted by FACS at 6 weeks (D) and 12 weeks (E) of differentiation, then plated on a Matrigel-coated plate. MHC, MYOG, and DAPI were detected by immunohistochemistry at 14 days after sorting. Scale bars, 50 μm.(F) Time course of the mRNA expression of *MYF5*, *PAX3*, *PAX7*, *MYOD1*, and *MYOG* in sorted MYF5+ and MYF5− cells during differentiation from 6 to 12 weeks. Data of three independent experiments are shown as means ± SD. ^∗^p \< 0.05, ^∗∗^p \< 0.01, versus MYF5− cells.

Video S1. Spontaneous Twitching of Differentiated Myotubes70 days after differentiation of MYF5-tdTomato C3 hiPSCs, spontaneous twitching of differentiated myotubes was observed in whole area of culture dish. This video was taken by BZ-X700 (Keyence, Osaka, Japan).

Myogenic Lineage Tracing by Monitoring MYF5 Expression {#sec2.3}
------------------------------------------------------

Next, we generated a MYF5-tdTomato reporter hiPSC line to visualize myogenic specification in the differentiation culture using the CRISPR/Cas9 system ([Figure S4](#mmc1){ref-type="supplementary-material"}A). We obtained two heterozygous targeted clones (C3 and E16) ([Figure S4](#mmc1){ref-type="supplementary-material"}B) and one homozygous clone (A24). Upon applying the myogenic differentiation protocol to MYF5-tdTomato C3 hiPSCs, we detected tdTomato-positive cells by flow cytometry after 4 weeks of differentiation in these three clones ([Figures 3](#fig3){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}C). The MYF5 expression in tdTomato-positive cells was confirmed by RT-PCR ([Figure S4](#mmc1){ref-type="supplementary-material"}D). During the myogenic differentiation, MYF5-tdTomato-positive cells gradually increased and peaked around 20% after 10 weeks of differentiation ([Figure 3](#fig3){ref-type="fig"}B). The MYF5-tdTomato-positive cells made a cluster in the early differentiation stage ([Figures 3](#fig3){ref-type="fig"}C and [S5](#mmc1){ref-type="supplementary-material"}, upper panel), but were observed diffusely and surrounded by myotubes in the late differentiation stage ([Figure 3](#fig3){ref-type="fig"}C and [S5](#mmc1){ref-type="supplementary-material"}, lower panel). Next, we assessed the *in vitro* myogenic differentiation potential of MYF5-tdTomato-positive and -negative cells. In the early differentiation stage, MYF5-tdTomato-positive cells demonstrated robust myogenic potential, while the MYF5-tdTomato-negative cells showed limited myogenic differentiation ([Figure 3](#fig3){ref-type="fig"}D), suggesting that MYF5 is a suitable marker for the purification of myogenic progenitors in the early stage. On the other hand, in the late differentiation stage, both MYF5-tdTomato-positive and -negative cells showed robust myogenic differentiation potential ([Figure 3](#fig3){ref-type="fig"}E). Gene expression profiling of myogenic marker genes was carried out to characterize the MYF5-tdTomato-positive cells. *MYF5* expression was confirmed for the quality of the mRNA samples from the purified cells ([Figure 3](#fig3){ref-type="fig"}F). *PAX3* was detected highly in the MYF5-tdTomato-positive population at the early differentiation period, but gradually decreased with differentiation ([Figure 3](#fig3){ref-type="fig"}F). On the other hand, the satellite cell marker, *PAX7*, was expressed dominantly in the late-stage MYF5-tdTomato-positive population and gradually increased with differentiation ([Figure 3](#fig3){ref-type="fig"}F). No significant difference in the expression of the myogenic master regulator *MYOD1* was seen between the MYF5-tdTomato-positive and -negative populations at 12 weeks differentiation ([Figure 3](#fig3){ref-type="fig"}F). Intriguingly, a differentiated myocyte marker, *MYOG*, was expressed more in the late-stage MYF5-tdTomato-negative population than the late-stage positive population ([Figure 3](#fig3){ref-type="fig"}F). These data suggest that the characteristics of the MYF5-tdTomato-positive and -negative populations vary from early differentiation to late differentiation.

Comparison of Myogenic Marker Expression between Early- and Late-Stage Cells {#sec2.4}
----------------------------------------------------------------------------

Next, we conducted an immunocytochemistry assay to analyze myogenic marker expressions at the protein level in the MYF5-tdTomato-positive and -negative populations ([Figures 4](#fig4){ref-type="fig"}A and 4B). Approximately 15% of the early-stage and 50% of the late-stage MYF5-tdTomato-positive population were positive for PAX7-positive cells ([Figures 4](#fig4){ref-type="fig"}A and 4B). On the other hand, the MYF5-tdTomato-negative population contained almost no PAX7-positive cells at any time ([Figures 4](#fig4){ref-type="fig"}A and 4B). It is possible that these cells contain differentiated myocytes, which were initially MYF5 positive and subsequently downregulated this gene with proceeding differentiation. To identify differentiated myocytes, MYOG expressions were analyzed ([Figures 4](#fig4){ref-type="fig"}C and 4D). The MYF5-tdTomato-negative population contained significantly more MYOG-positive cells than the MYF5-tdTomato-positive population both in early and later stages ([Figures 4](#fig4){ref-type="fig"}C and 4D). The proportion of MYOG-positive cells was increased from 22% to 35% in the MYF5-tdTomato-negative population during differentiation. Taken together with the observation that the late-stage MYF5-tdTomato-negative population also showed robust myogenic differentiation potential ([Figure 3](#fig3){ref-type="fig"}E), the late-stage MYF5-tdTomato-negative population contains differentiated myogenic cells rather than myogenic progenitor cells.Figure 4Comparison of Myogenic Marker Expression between Early- and Late-Stage Differentiation(A) Immunocytochemistry of PAX7+ and MYOD1+ in sorted MYF5+ and MYF5− cells at 4 or 12 weeks of differentiation. Scale bar, 50 μm.(B) Branching index of PAX7+, MYOD1+, and MYOD1+PAX7+ cells in sorted MYF5+ and MYF5− cells. Data shown are from three biological replicates.(C) Immunocytochemistry of DAPI and MYOG in sorted MYF5+ and My5− cells at 6 and 12 weeks of differentiation. Scale bar, 50 μm.(D) The box diagram shows the percentage of MYOG+ in DAPI+ cells. Data of three independent experiments are shown as means ± SD. ^∗∗∗^p \< 0.001 using Student\'s t test.(E) Ward\'s linkage using Euclidean distances.(F) Heatmap of fetal marker gene expression in MYF5+ cells differentiated for 6, 10, or 11 weeks (green is low expression and red is high expression).(G) Bar charts indicate the relative transcript levels of fetal markers in MYF5+ cells at 6, 10, and 11 weeks by qPCR. Data of three independent experiments are shown as means ± SD. ^∗^p \< 0.05, ^∗∗∗^p \< 0.001 using one-way ANOVA.

Notably, PAX7-positive MuSC-like cells were dominantly detected in the MYF5-tdTomato-positive population at late-stage differentiation. Intriguingly, a dendrogram of comprehensive mRNA expression profiling by RNA sequencing (RNA-seq) showed that late-stage MYF5-tdTomato-positive cells clustered nearer to late-stage MYF5-tdTomato-negative cells than to early-stage MYF5-tdTomato-positive cells ([Figure 4](#fig4){ref-type="fig"}E). The transcription factor *NFIX* is a fetal-specific transcription factor in developing skeletal muscle ([@bib27]). A later study identified a number of differentially expressed genes between embryonic and fetal muscle progenitor cells ([@bib29]). Based on those studies, we compared embryonic and fetal marker genes expressions between early- and late-stage MYF5-tdTomato-positive cells and found that fetal marker genes were highly expressed in late-stage MYF5-tdTomato-positive cells ([Figures 4](#fig4){ref-type="fig"}F and 4G), whereas embryonic marker genes were highly expressed in early-stage MYF5-tdTomato-positive cells ([Figure S4](#mmc1){ref-type="supplementary-material"}E). In hiPSCs induced toward myogenic differentiation, MYF5-positive cells adopted a fetal phenotype while concomitantly losing embryonic molecular markers, indicating that the characteristics of MYF5-positive cells depends on the stage of differentiation.

Muscle Regeneration Potential of MYF5-tdTomato-Positive Cells {#sec2.5}
-------------------------------------------------------------

To assess their muscle regeneration potential, MYF5-tdTomato-positive and -negative cells were purified, and 3 × 10^5^ cells of each population were transplanted into the cardiotoxin-treated tibialis anterior (TA) muscles of immunodeficient mice ([Figure 5](#fig5){ref-type="fig"}). Although MYF5-tdTomato-positive cells both at the early and late stage of differentiation showed muscle regeneration potential based on the detection of human SPECTRIN-positive mouse muscle fibers, including human nuclei ([Figures 5](#fig5){ref-type="fig"}A and 5B), the number of SPECTRIN-positive muscle fibers was much higher with the late-stage cell transplantation ([Figure 5](#fig5){ref-type="fig"}C). These results suggest that late-stage MYF5-tdTomato-positive cells have higher muscle regeneration potential than early-stage cells *in vivo.* In contrast, MYF5-tdTomato-negative cells of all differentiation stages showed almost no muscle regeneration ([Figures 5](#fig5){ref-type="fig"}A and 5B). When MYF5-tdTomato-negative cells were transplanted, engrafted cells were only detected in the interstitial area of the muscles and formed cyst-like structures ([Figures 5](#fig5){ref-type="fig"}A and 5B). These engrafted human cells in the interstitial area were negative for both MYOD1 and MYOG ([Figure S6](#mmc1){ref-type="supplementary-material"}). Furthermore, very few SPECTRIN-positive muscle fibers were detected ([Figure 5](#fig5){ref-type="fig"}C). These results demonstrate that muscle progenitor cells with muscle regeneration potential can be purified by MYF5 expression during the induction of myogenic differentiation in hiPSCs.Figure 5Muscle Regeneration Potential of MYF5-tdTomato+ CellsSorted MYF5+ or MYF5− cells were transplanted into the cardiotoxin-treated TA muscles of immunodeficient mice, and the engrafted cells were evaluated by immunohistochemistry 4 weeks after the transplantation. Immunohistochemistry of human SPECTRIN (green), human nuclei (red), LAMININ α2 (white), and DAPI (blue) in sorted 6-week differentiated (A) and 12-week differentiated (B) MYF5+/− cells. Scale bars, 50 μm. (C) Graphs quantifying the number of engrafted myofibers in one TA muscle. Data of three independent experiments are shown as means ± SD. ^∗^p \< 0.05 using one-way ANOVA.

DYSTROPHIN Restoration by MYF5-tdTomato-Positive Cell Transplantation in DMD Model Mice {#sec2.6}
---------------------------------------------------------------------------------------

Subsequently, we assessed the DYSTROPHIN restoration potential of MYF5-tdTomato-positive cells by transplanting them into DMD-null/NSG model mice ([Figure 6](#fig6){ref-type="fig"}). Many reports have demonstrated DYSTROPHIN restoration by hiPSC-derived muscle progenitor engraftment. However, most did so after inducing muscle injury by cardiotoxin injection or forced running before the cell transplantation to enhance the engraftment. However, those pretreatments should be avoided in clinical application. Therefore, no pretreatment was done in our transplantation study. Based on the results of [Figure 5](#fig5){ref-type="fig"}, we used late-stage MYF5-tdTomato-positive cells for the cell transplantation. We found human LAMIN A/C-positive nuclei were mainly detected in host muscle fibers that were DYSTROPHIN positive ([Figure 6](#fig6){ref-type="fig"}A), suggesting that MYF5-tdTomato-positive cells at 12 weeks differentiation robustly regenerated the muscle of DMD-null/NSG mice. More than 100 DYSTROPHIN-positive muscle fibers were regenerated on average at 4 weeks after the transplantation ([Figure 6](#fig6){ref-type="fig"}B). At 2 weeks after transplantation, DYSTROPHIN-positive muscle fibers were smaller than normal muscle fibers, and many transplanted human cells exited the interstitial area of the muscle ([Figure S7](#mmc1){ref-type="supplementary-material"}A). At 3 months after transplantation, the size of the DYSTROPHIN-positive fibers was comparable with the host myofibers, and the transplanted cells in the interstitial area had dramatically decreased ([Figure S7](#mmc1){ref-type="supplementary-material"}A). On the other hand, MYF5-tdTomato-negative cells engrafted in the interstitial area of muscle fibers formed cyst-like structures even in the muscle of DMD model mice ([Figure 6](#fig6){ref-type="fig"}A) with very few DYSTROPHIN-positive muscle fibers ([Figure 6](#fig6){ref-type="fig"}B). Although MYF5-tdTomato-positive cells were engrafted as myonuclei, indicating their location within the DYSTROPHIN-positive membrane, several engrafted cells were located outside the DYSTROPHIN-positive plasma membrane and inside the LAMININ α2-positive basement membrane, which has been reported as the specific position of muscle satellite cells ([@bib26]) ([Figure 6](#fig6){ref-type="fig"}C, white arrowheads). Some human LAMIN A/C-positive engrafted cells expressed PAX7 ([Figure 6](#fig6){ref-type="fig"}D), indicating that some engrafted MYF5-tdTomato-positive cells distributed spatially like satellite cells. Approximately 4% of human nuclei were located in the specific niche position (data not shown). Moreover, MYOD1 expression indicated that some human LAMIN A/C-positive cells were located outside of the muscle fibers at 4 weeks after transplantation ([Figure 6](#fig6){ref-type="fig"}E). These MYF5-tdTomato-positive cell-derived MYOD1-positive cells were sometimes located near the embryonic-type myosin heavy chain 3 (MYH3)-positive regenerating myofibers ([Figure S7](#mmc1){ref-type="supplementary-material"}B), suggesting that repeated muscle regeneration might occur by human myoblasts expanded from the engrafted hiPSC-derived MuSCs.Figure 6DYSTROPHIN Restoration by MYF5-tdTomato+ Cell Transplantation in DMD Model MiceSorted MYF5+ or MYF5− cells were transplanted into the TA muscles of DMD-null/NSG model mice, and the engrafted cells were evaluated by immunohistochemistry 4 weeks after the transplantation.(A) Immunohistochemistry of human LAMIN A/C (green), DYSTROPHIN (red), and DAPI (blue) in sorted 12-week differentiated MYF5+/− cells. Left and right images show different positions of the muscles under the same conditions. Magnification, 200×.(B) Number of engrafted myofibers in one TA muscle. Data of four independent experiments are shown as means ± SD. ^∗∗^p \< 0.01 using Student\'s t test.(C) Immunohistochemistry of human LAMIN A/C (green), DYSTROPHIN (red), LAMININ α2 (white), and DAPI (blue) in sorted 12-week differentiated MYF5+/− cells. White arrowheads show human nuclei inside the LAMININ α2+ basement membrane and outside the DYSTROPHIN+ plasma membrane. Magnification, 400×.(D) Immunohistochemistry of human LAMIN A/C (green), PAX7 (red), LAMININ α2 (white), and DAPI (blue) in sorted 12-week differentiated MYF5+/− cells. White arrowheads show that engrafted human LAMIN A/C+ cells were also PAX7+ cells. Magnification, 400×.(E) Immunohistochemistry of human LAMIN A/C (green), MYOD1 (red), LAMININ α2 (white), and DAPI (blue) in sorted 12-week differentiated MYF5+/− cells. White arrowheads show that engrafted human LAMIN A/C+ cells were also MYOD1+ cells. Magnification, 200×. Scale bars, 50 μm.

Functional Recovery of DMD Model Mice after DYSTROPHIN Restoration {#sec2.7}
------------------------------------------------------------------

Finally, we assessed the functional feature of DMD-null/NSG mice after the MYF5-tdTomato-positive cell transplantation. We used a muscle contraction force assessment system on living mice with anesthesia for the assessment. One to two million MYF5-tdTomato-positive cells were transplanted into the right gastrocnemius of DMD-null/NSG mice, and maximum muscle contraction force of both sides of the gastrocnemius was analyzed at 2, 4, and 6 weeks after the transplantation. No difference in muscle force between the two sides was detected at 2 and 4 weeks after transplantation (data not shown), but a slight but nevertheless significant increase in force was detected in all three transplanted gastrocnemius muscles compared with the contralateral sham-operated muscles at 6 weeks ([Figure 7](#fig7){ref-type="fig"}). These results suggest that the restoration of DYSTROPHIN-positive muscle fibers could contribute to the amelioration of muscle function in DMD model mice.Figure 7Functional Recovery of DMD Model Mice after DYSTROPHIN Restoration(A) Maximum muscle force of MYF5+ cell-transplanted leg (right) and sham leg (left) in DMD mouse. The maximum force of the sham was used as the control.(B) Maximum muscle force of the MYF5+-transplanted leg relative to the shammed leg. Data of three independent experiments are shown as means ± SD. ^∗^p \< 0.05 using Student\'s t test.

Discussion {#sec3}
==========

In this study, we succeeded in identifying MuSCs derived from hiPSCs following myogenic developmental steps. Our results reveal the following three main points. First, the long-term application of high-concentration WNT agonists induces dermomyotome cells in more than 90% of differentiated cells. Second, the characteristics of the MYF5-positive cells vary between the early and late differentiation stages. During the differentiation process, MYF5-tdTomato-positive cells gradually mature and finally acquire characteristics resembling fetal MuSCs. Third, late-stage MYF5-tdTomato-positive cells have muscle regeneration potential, which recovers DYSTROPHIN and improves muscular function of the limbs that received the transplant in DMD-null/NSG model mice. We propose that these late-stage MYF5-positive cells should be explored for their cell therapy potential in DMD.

To induce dermomyotome-like cells, a lower dose or short exposure time of a WNT agonist was used in previous reports ([@bib8], [@bib9], [@bib11], [@bib18], [@bib44]). In this study, however, we optimized a long-term protocol with a higher WNT agonist dose. The induction efficiency of PAX3+ CD271− cells was 45% at day 6 and 90% at day 12, which was significantly higher than previous reports. These results suggest that dermomyotome-like cell populations continue to increase with exposure to the WNT agonist. Moreover, if the induction medium was converted to myogenic differentiation medium within the first 8 days of the protocol, then almost no MYF5-tdTomato-positive cells were detected in the following stage (data not shown). Thus, we consider the marked increase of the differentiation efficiency of dermomyotome cells important for myogenic differentiation.

Comprehensive analysis of the transcriptome revealed that early- and late-stage MYF5-tdTomato-positive cells are markedly distinct, with late-stage MYF5-tdTomato-positive cells more resembling late-stage MYF5-tdTomato-negative cells. Early-stage MYF5-tdTomato-positive cells highly expressed *PAX3* and embryonic markers, but weakly expressed *PAX7* and fetal markers, suggesting that these cells are embryonic myogenic progenitor cells ([@bib29], [@bib39]). After 10--12 weeks of differentiation, however, these cells decreased their expression of *PAX3* and gradually increased their expression of *PAX7* and *MYOD1*, and increased their expression of fetal markers, suggesting a similarity with fetal MuSCs ([@bib22], [@bib29], [@bib36], [@bib43]). In human development, characterization of human fetal MCAM-positive cells in skeletal muscle demonstrated that CD82 is the marker of fetal muscle progenitors ([@bib2]). In their dataset, we identified that *COL15A1*, *CRYAB*, *DLK1*, and *CD82* were well correlated to our RNA-seq data, suggesting that some of the characteristics of fetal MuSCs are conserved between mouse and human. Furthermore, we found that late-stage MYF5-tdTomato-positive cells localized near myocytes and myotubes. Thus, we hypothesize that myocytes and myotubes might provide an essential niche for the induction of MuSCs. Further research is needed to determine both the origin and the niche of MuSCs in the hiPSC differentiation culture. In contrast, we found that the late-stage MYF5-tdToamto-negative population expressed MYOG dominantly, suggesting that the MYF5-tdTomato-negative cells were mainly composed of differentiated myocytes that might have once expressed MYF5 in the early stage. Furthermore, while up to 40% of the MYF5-tdTomato-negative cells were MYOG positive, approximately half of the cells were non-myogenic cells. Since the MYOG expression promotes cell-cycle withdrawal ([@bib3]), these differentiated myocytes could hardly contribute to muscle regeneration. The last non-myogenic cells in the MYF5-tdTomato-negative population were composed of neural cells, mesenchymal cells, and so on (data not shown). Most of the engrafted cells from MYF5-tdTomato-negative cells were non-myogenic cells, suggesting that the engrafted cells might be mainly derived from non-myogenic cells rather than from post-mitotic differentiated myocytes.

Among reported hiPSC-derived MuSCs, iPAX7 is believed to fuse to host muscles in DMD model mice most effectively ([@bib13]). Muscle progenitors prepared using a transgene-free method have lower regenerative potential, and PAX7 overexpression in the progenitors is reported to enhance their regenerative potential ([@bib20]). Our transgene-free protocol, on the other hand, has comparable regeneration potential as transgene protocols. Differentiating hiPSCs to MuSCs, which we defined as late-stage MYF5-positive cells, resulted in fusion with more than 100 muscle fibers in DMD model mice and converting the fibers to DYSTROPHIN-positive by a single administration.

Notably, most previous studies induced muscle injury by cardiotoxin injection as a pretreatment ([@bib13], [@bib11], [@bib18], [@bib4]) to enhance the fusion efficiency of the engrafted cells ([@bib12]). However, such an invasive pretreatment is not applicable clinically. In contrast, our method based on no pretreatment is more consistent with clinical conditions in which the patient will not undergo a treatment to induce the muscle damage.

In conclusion, we developed a novel method in which hiPSCs are differentiated into MuSCs by recapitulating myogenic developmental steps. We found that the resultant MuSCs, which were marked by MYF5 expression at the late stage of the differentiation protocol, have high regeneration potential in DMD model mice. Further optimization of the protocol, namely purification using cell surface markers instead of the MYF5 reporter line, using clinical iPSC stocks and evaluation of the long-term safety after engraftment, could contribute to an effective cell therapy for DMD and other degenerative muscular diseases.

Experimental Procedures {#sec4}
=======================

Ethical Approval {#sec4.1}
----------------

Ethical approval for this study was granted by the Ethics Committee on Human Stem Cell Research, Institute for Frontier Medical Sciences, Kyoto University, and Kyoto University Hospital. All mouse experiments were carried out according to protocols approved by the Animal Research Committee of Kyoto University.

Transplantation Studies {#sec4.2}
-----------------------

NSG mice were purchased from Charles River Laboratories. Eight- to 10-week-old NSG mice were anesthetized with isoflurane (Abbvie), and 50 μL of 1 μM cardiotoxin (Latoxian) was injected in both TA muscles before intramuscular cell transplantation. Twenty-four hours after the cardiotoxin damage, 3 × 10^5^ of MYF5-tdTomato-positive and -negative cells at 6--12 weeks differentiation were injected into the left TA muscles, while the right TA muscles were used as the sham-operated control. One month after transplantation, mice were sacrificed, and TA muscle samples were collected and analyzed by immunohistochemical staining. NSG mice were also mated with DMD-null mice ([@bib23]) to generate DMD-null/NSG mice for the *in vivo* transplantation studies as a DMD model. Five- to 8-week-old DMD-null/NSG mice were anesthetized with isoflurane without any pretreatment, and 3 × 10^5^ of MYF5-tdTomato-positive and -negative cells at 12 weeks differentiation were injected into the left and right TA muscles, respectively. The mice were sacrificed 2, 4, and 12 weeks after transplantation, and TA muscle samples were collected and analyzed by immunohistochemical staining.

Statistical Analysis {#sec4.3}
--------------------

For human DYSTROPHIN-positive myofiber data and muscle force data, unpaired Student's t tests were calculated. For human SPECTRIN-positive data and qRT-PCR data, one-way ANOVA was calculated. Differences were considered significant for p values ≤0.05.

Other Materials and Methods {#sec4.4}
---------------------------

Other materials and methods are described in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Data and Code Availability {#sec4.5}
--------------------------

The accession number for the RNA-sequencing data reported in this paper is DDBJ: DRA010291[DRA010291](ncbi-p:DRA010291){#intref0010}.
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